Cargando…
Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (PD-1), anti-programmed cell death protein ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibodies, are novel therapeutic agents widely used in numerous malignancies. They are known...
Autores principales: | Angelousi, Anna, Papalexis, Petros, Karampela, Athina, Marra, Marianna, Misthos, Dimitrios, Ziogas, Dimitriοs, Gogas, Helen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748697/ https://www.ncbi.nlm.nih.gov/pubmed/36561623 http://dx.doi.org/10.3892/etm.2022.11709 |
Ejemplares similares
-
The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events
por: Mytareli, Chrysoula, et al.
Publicado: (2023) -
An overview of antibody–drug conjugates in oncological
practice
por: Theocharopoulos, Charalampos, et al.
Publicado: (2020) -
Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review
por: Ziogas, Dimitrios C., et al.
Publicado: (2021) -
Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al
por: Ziogas, Dimitrios C, et al.
Publicado: (2021) -
Clinical considerations about the coexistence of melanoma and chronic
lymphocytic leukemia in the era of targeted therapies, triggered by rare
clinical scenarios. A case series and review of the literature
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2020)